Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rilvegostomig + recombinant human hyaluronidase
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
rilvegostomig + recombinant human hyaluronidase is a subcutaneous combination therapy being developed by AstraZeneca for the treatment of advanced solid tumors. The formulation consists of rilvegostomig (AZD2936), a bispecific monoclonal antibody that targets both programmed cell death protein 1 (PD-1) and T-cell immunoreceptor with Ig and ITIM domains (TIGIT), and recombinant human hyaluronidase (rHu). Rilvegostomig is designed to enhance antitumor immune activity by simultaneously blocking two key inhibitory checkpoints on T cells. The recombinant human hyaluronidase component acts as a permeation enhancer by temporarily degrading hyaluronan in the subcutaneous extracellular matrix, which facilitates the delivery and absorption of large volumes of the bispecific antibody. This combination is currently being evaluated in the Phase I ARTEMIDE-subQ trial to compare its pharmacokinetics and safety with intravenous administration of rilvegostomig.
- Other names
- SC rilvegostomigrilvegostomig subcutaneousrHurHuPH20rHuPH-20rHuPH 20
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on rilvegostomig + recombinant human hyaluronidase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rilvegostomig + recombinant human hyaluronidase.